Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Castration-resistant Prostate Cancer: early-phase trial registry
7 of 16 indexed Castration-resistant Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 7 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Castration-resistant Prostate Cancer: 16 US clinical trials tracked, 7 recruiting.
Castration-resistant Prostate Cancer is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is Exelixis, running 2 of these trials.
Enrollment posture brief
Registry condition castration-resistant-prostate-cancer
OPEN 7 | RECR 44% | LATE 2 | EARLY 12 | RANK #1060 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Distress Syndrome (44% recruiting · 32 trials)
Castration-resistant Prostate Cancer lists 7 open slots (44% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Castration-resistant Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Castration-resistant Prostate Cancer is recruiting below its size-band peers.
7 of 16 indexed trials (43.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Castration-resistant Prostate Cancer trials is spread across many organizations.
Exelixis accounts for 2 of 16 trials (12.5%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Castration-resistant Prostate Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 16 trials that report a genuine target (sentinel values excluded). 10 of those (62.5%) plan for fewer than 100 participants.
-
Castration-resistant Prostate Cancer research is mostly interventional.
15 interventional and 1 observational studies make up this index (93.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Mayo Clinic
NCT06378866
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Duke University
NCT06141993
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Edwin Posadas, MD
NCT05534646
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
OHSU Knight Cancer Institute
NCT05919329
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Deciphera Pharmaceuticals
NCT06966024
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
Rana McKay, MD
NCT05502315
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
Virginia Commonwealth University
NCT06636123
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT03170960
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
NCT04090528
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Exelixis
NCT01605227
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
Progenics Pharmaceuticals
NCT03939689
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
NCT04580485
Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
Io Therapeutics
NCT01540071
Testosterone Therapy in Castration Resistant Prostate Cancer
University of Colorado, Denver
NCT03734653
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
NCT02207504
Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer
UNC Lineberger Comprehensive Cancer Center
NCT03672396
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 6 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Castration-resistant Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Castration-resistant Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Castration-resistant Prostate Cancer page
16 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Castration-resistant Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Exelixis sponsors the most Castration-resistant Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Exelixis's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Castration-resistant Prostate Cancer condition card totals 16 registered trials; most-linked intervention cabozantinib; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.